|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,943.00 INR | -0.96% |
|
+0.02% | +12.98% |
| 07-21 | South Africa regulator reviews 12 generic semaglutide applications | RE |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| Market Cap | 4,662B 48.28B 42.31B 39.33B 36.1B 68.02B 69.07B 468B 183B 2,269B 181B 177B 7,877B | P/E 2027 * |
35.5x | P/E 2028 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 4,389B 45.45B 39.83B 37.02B 33.99B 64.03B 65.02B 441B 172B 2,136B 171B 167B 7,415B | EV / Sales 2027 * |
6.71x | EV / Sales 2028 * | 5.92x |
| Free-Float |
44.39% | Yield 2027 * |
0.82% | Yield 2028 * | 0.91% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.96% | ||
| 1 week | +0.02% | ||
| Current month | +4.32% | ||
| 1 month | +5.70% | ||
| 3 months | +16.68% | ||
| 6 months | +20.47% | ||
| Current year | +12.98% |
| 1 week | 1,922.5 |  | 1,966.5 |
| 1 month | 1,855.9 | | 1,966.5 |
| Current year | 1,583.7 | | 1,966.5 |
| 1 year | 1,548 | | 1,966.5 |
| 3 years | 1,068.35 | | 1,966.5 |
| 5 years | 672.55 | | 1,966.5 |
| 10 years | 312 | | 1,966.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.96% | +0.02% | +14.81% | +77.10% | 48.88B | |
| -0.99% | -0.27% | +66.69% | +108.95% | 35.72B | |
| -1.21% | -1.60% | -3.99% | +34.91% | 12.02B | |
| -1.47% | -0.64% | +16.11% | +83.68% | 11.84B | |
| -0.37% | +0.94% | +34.42% | +136.73% | 8.95B | |
| +0.33% | -1.13% | +50.36% | -5.96% | 6.91B | |
| -0.34% | -2.41% | +14.20% | +33.03% | 6.78B | |
| -1.88% | -4.56% | +0.69% | +192.09% | 6.57B | |
| -2.47% | -5.28% | -33.67% | +6.76% | 5.81B | |
| -3.26% | +1.47% | +24.55% | +145.02% | 4.64B | |
| Average | -1.26% | -1.51% | +18.42% | +81.23% | 14.81B | |
| Weighted average by Cap. | -1.08% | -0.20% | +26.50% | +84.06% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.77B 5.94B 5.52B 5.07B 9.54B 9.69B 65.69B 25.67B 318B 25.42B 24.88B 1,105B | 729B 7.55B 6.62B 6.15B 5.65B 10.64B 10.81B 73.25B 28.62B 355B 28.35B 27.74B 1,232B |
| Net income | 133B 1.37B 1.2B 1.12B 1.03B 1.93B 1.96B 13.32B 5.2B 64.54B 5.15B 5.04B 224B | 157B 1.62B 1.42B 1.32B 1.21B 2.28B 2.32B 15.72B 6.14B 76.21B 6.09B 5.96B 265B |
| Net Debt | -273B -2.83B -2.48B -2.3B -2.12B -3.99B -4.05B -27.44B -10.72B -133B -10.62B -10.39B -462B | -341B -3.54B -3.1B -2.88B -2.64B -4.98B -5.06B -34.29B -13.4B -166B -13.27B -12.99B -577B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/07/26 | ₹1,943.00 | -0.96% | 1,718,430 |
| 21/07/26 | ₹1,961.90 | +0.28% | 1,412,579 |
| 20/07/26 | ₹1,956.40 | +1.23% | 1,676,034 |
| 17/07/26 | ₹1,932.60 | -0.90% | 2,475,664 |
| 16/07/26 | ₹1,950.10 | -0.07% | 1,396,189 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
